Open AccessThe Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas’ Psoriasis Registry
Author(s) -
Mark Lebwohl,
Rose Anne Medeiros,
Rachel H. Mackey,
Leslie R. Harrold,
Wendell C. Valdecantos,
Mary Flack,
Amanda Golembesky,
Nirali Kotowsky,
Bruce Strober
Publication year - 2022
Publication title -
journal of psoriasis and psoriatic arthritis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.473
H-Index - 3
eISSN - 2475-5311
pISSN - 2475-5303
DOI - 10.1177/24755303221079814
Subject(s) - psoriasis , medicine , interquartile range , plaque psoriasis , depression (economics) , quality of life (healthcare) , disease , anxiety , dermatology , severity of illness , generalized pustular psoriasis , physical therapy , psychiatry , nursing , economics , macroeconomics
Background: Generalized pustular psoriasis (GPP) is a rare, systemic disease characterized by persistent or recurrent flares of painful neutrophilic pustules. There is limited real-world evidence characterizing patients with GPP. Objectives: To establish the distinguishing characteristics of GPP relative to plaque psoriasis, and help inform future treatment decisions and improve patient outcomes. Methods: North American adults with GPP or plaque psoriasis (without pustules) identified from CorEvitas’ Psoriasis Registry were included in this dataset. Registry enrollment data, including patient sociodemographics, disease characteristics, medication use, and patient-reported outcome measures were compared for patients with GPP vs those with plaque psoriasis. This study was descriptive, and no hypothesis tests were performed. Results: In this sample, patients with GPP (N = 60) reported greater median (interquartile range) pain (20 [3-62] vs 5 [0-35]), fatigue (44 [15-73] vs 20 [4-50]), and itch (59 [10-85] vs 22 [5-70]) than those with plaque psoriasis (N = 4894). Descriptively, patients with GPP also reported more anxiety and depression (EQ-5D-3L: 38% vs 26%) and had more treatment experience (≥2 previous systemics: 15% vs 7%). Conclusions: A greater degree of symptom severity and impact on quality of life was reported by patients with GPP compared with plaque psoriasis in this sample. Importantly, patients with GPP had more treatment experience, suggesting that current treatment options do not adequately resolve the disease—highlighting the need to develop more effective GPP treatments.